Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
HEPATOCELLULAR CARCINOMA BY THE NUMBERSHEPATOCELLULAR CARCINOMA (HCC) IS THE MOST COMMON TYPE OF
PRIMARY LIVER CANCER, ACCOUNTING FOR 90 PERCENT OF ALL LIVER CANCERS.
841,000APPROXIMATELY
PEOPLE AROUND THE WORLD ARE
DIAGNOSED WITH LIVER CANCER EACH YEAR
APPROXIMATELY 1 IN 12 CANCER DEATHS ARE DUE TO LIVER CANCER
LIVER CANCER IS THE FOURTH LEADING
CAUSE OF CANCER MORTALITY WORLDWIDE
AND OCCURS MORE OFTEN IN MEN THAN WOMEN.
597,000245,000
CASES PER YEAR
MEDIAN AGE
63
67
AT DIAGNOSIS
AT DEATH
EUROPE
CENTRALAMERICA
SOUTH AMERICA
AFRICA64,800
41,900
11,200
24,2002,900
82,500
AUSTRALIA & NEW ZEALAND
NORTH AMERICA
ASIA
Source: GLOBOCAN 2018
609,600
LIVER CANCER “HOT SPOTS” SURVIVAL RATES
HCC IN ADULTS IS OFTEN DIAGNOSED
IN LATER STAGES, WHICH RESULTS IN
RELATIVELY LOW 5-YEAR SURVIVAL RATES.
LIVER CANCER 5-YEAR RELATIVE SURVIVAL RATES BY STAGE AT DIAGNOSIS
LOCALIZED
31%
DISTANT
3%
UNSTAGED
6%
BETWEEN 80 AND 90
PERCENT OF ALL HCC
CASES WORLDWIDE ARE
CAUSED BY INFECTION
WITH THE HEPATITIS B
VIRUS (HBV) OR
HEPATITIS C VIRUS (HCV)
COMMON HCC RISK FACTORS
HEAVYALCOHOL
USE
OBESITY NON-ALCOHOLIC STEATOHEPATITIS
(NASH)
GENDER TYPE 2DIABETES
RACE/ETHNICITY
CERTAINGENETIC
SYNDROMES
CIRRHOSISCHRONICHCV/HBV
INFECTION
SIGNS & SYMPTOMS
UNINTENDED WEIGHT LOSSLOSS OF APPETITENAUSEA OR VOMITINGENLARGED LIVER AND/OR SPLEENABDOMINAL PAIN AND/OR SWELLINGITCHINGYELLOWING OF THE SKIN AND EYES
TREATMENT OPTIONS
A PATIENT’S TREATMENT OPTIONS ARE LARGELY
DEPENDENT ON STAGE OF DISEASE & MAY INCLUDE:
SURGERY RADIATIONTHERAPY
CHEMOTHERAPY IMMUNOTHERAPY TARGETEDDRUG THERAPY
TUMOR ABLATION OR EMBOLIZATION
REGIONAL
11%
© 2018 Bristol-Myers Squibb Company